Microbot Medical Inc. (NASDAQ:MBOT) Director Yoseph Bornstein sold 53,000 shares of Microbot Medical stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $1.20, for a total value of $63,600.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Yoseph Bornstein also recently made the following trade(s):

  • On Tuesday, September 26th, Yoseph Bornstein sold 50,000 shares of Microbot Medical stock. The stock was sold at an average price of $1.24, for a total value of $62,000.00.
  • On Tuesday, September 19th, Yoseph Bornstein sold 50,000 shares of Microbot Medical stock. The stock was sold at an average price of $1.18, for a total value of $59,000.00.
  • On Tuesday, September 12th, Yoseph Bornstein sold 20,000 shares of Microbot Medical stock. The stock was sold at an average price of $1.12, for a total value of $22,400.00.
  • On Wednesday, September 6th, Yoseph Bornstein sold 45,610 shares of Microbot Medical stock. The stock was sold at an average price of $1.01, for a total value of $46,066.10.

Shares of Microbot Medical Inc. (NASDAQ:MBOT) remained flat at $1.37 on Thursday. The company had a trading volume of 4,604,074 shares. The stock’s market cap is $60.34 million. The company’s 50 day moving average price is $1.13 and its 200-day moving average price is $2.66. Microbot Medical Inc. has a 1-year low of $1.00 and a 1-year high of $15.66.

Microbot Medical (NASDAQ:MBOT) last released its earnings results on Monday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.44. Equities research analysts expect that Microbot Medical Inc. will post ($25.02) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/10/05/microbot-medical-inc-mbot-director-sells-63600-00-in-stock.html.

A number of hedge funds have recently added to or reduced their stakes in the stock. Sabby Management LLC acquired a new stake in Microbot Medical during the second quarter valued at approximately $1,825,000. Vanguard Group Inc. lifted its stake in Microbot Medical by 252.2% during the second quarter. Vanguard Group Inc. now owns 159,992 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 114,561 shares during the last quarter. Finally, Bank of Montreal Can lifted its stake in Microbot Medical by 90,909.1% during the first quarter. Bank of Montreal Can now owns 20,022 shares of the biotechnology company’s stock valued at $116,000 after purchasing an additional 20,000 shares during the last quarter. 4.72% of the stock is owned by institutional investors and hedge funds.

Microbot Medical Company Profile

Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.

Receive News & Ratings for Microbot Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.